Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced on October 1, 2025 that its injectable ibuprofen product has received regulatory approval in Mexico. The approval was obtained through a partnership with PiSA Farmaceutica, which will hold exclusive supply and distribution rights for the product in the Mexican market.
The approved product is a proprietary intravenous ibuprofen formulation designed to manage pain and reduce fever in hospital and surgical settings. PiSA will launch the drug in 800 mg vials, a dosage that allows flexibility for a range of clinical uses and supports multimodal, opioid‑sparing pain management strategies.
Chief Executive Officer A.J. Kazimi said the approval “underscores the growing global need for effective non‑opioid pain management options and the strength of our collaboration with PiSA.” The entry into Mexico represents a significant expansion of CPIX’s international footprint and adds a new revenue source to its specialty pharmaceutical portfolio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.